IL1B and myocardial infarction: For instance, the results of the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study demonstrate that treatment with monoclonal IL-1β-neutralizing antibody canakinumab reduces the risk of recurrent cardiovascular events in patients with prior heart attack (Ridker et al., 2017).